Form 8-K - Current report:
SEC Accession No. 0001193125-19-274911
Filing Date
2019-10-25
Accepted
2019-10-25 17:16:21
Documents
12
Period of Report
2019-10-21
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d806364d8k.htm   iXBRL 8-K 24484
  Complete submission text file 0001193125-19-274911.txt   147003

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA atra-20191021.xsd EX-101.SCH 3072
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20191021_lab.xml EX-101.LAB 18141
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20191021_pre.xml EX-101.PRE 11410
13 EXTRACTED XBRL INSTANCE DOCUMENT d806364d8k_htm.xml XML 3425
Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 191170719
SIC: 2836 Biological Products, (No Diagnostic Substances)